Search clinical trials for: Dual receptor Tyrosine Kinase Inhibitor

Total 82082 results

BeiGene

Recruiting

Treatment of CD79B Mutant Relapsed/Refractory Diffuse Large B-Cell Lymphoma With Bruton Tyrosine Kinase Inhibitor Zanubrutinib

Relapsed Diffuse Large B-cell Lymphoma | Refractory Diffuse Large B-cell Lymphoma

China
Shayna Sarosiek, MD
AstraZeneca

Recruiting

ACALA-R In Predominantly Demyelinating IgM Mediated Neuropathy

Waldenstrom Macroglobulinemia | Neuropathy;Peripheral | IgM MGUS

United States
Medical University of South Carolina

Recruiting

COAST Therapy in Advanced Solid Tumors and Prostate Cancer (COAST)

Prostate Cancer Recurrent | Solid Tumor, Adult

United States
First Affiliated Hospital Xi'an Jiaotong University

Recruiting

A Study of Dasatinib Plus Reduced Intensive Consolidation Chemotherapy in Ph+ Adult ALL

Precursor Cell Lymphoblastic Leukemia-Lymphoma | ALL, Adult | Philadelphia-Positive Acute Lymphoblastic Leukemia

China
First Affiliated Hospital Xi'an Jiaotong University

Recruiting

A Study of TKI Maintenance Therapy Following Allo-HSCT in Newly Diagnosed Ph+ Adult ALL

Precursor Cell Lymphoblastic Leukemia-Lymphoma | ALL, Adult | Philadelphia-Positive Acute Lymphoblastic Leukemia

China
H. Lee Moffitt Cancer Center and Research Institute
Jazz Pharmaceuticals

Recruiting

Vyxeos Plus Gilteritinib in Relapsed or Refractory, FLT3-Mutated AML

Acute Myeloid Leukemia With FLT3/ITD Mutation

United States
Rennes University Hospital

Recruiting

Resistance to the Tyrosine Kinase Inhibitor Osimertinib and Pharmacokinetics in Non-small Cell Lung Cancer (RESISTYR)

Lung Cancer

France
Hunan Province Tumor Hospital

Recruiting

ALK Tyrosine Kinase Inhibitors in ALK-rearranged Advanced Squamous Cell Carcinoma (ATPase)

Non-small Cell Lung Cancer

China
Centre Leon Berard

Recruiting

Efficiency of Imatinib Treatment After 10 Years of Treatment in Patients With Gastrointestinal Stromal Tumours (GIST) (Gist-Ten)

C-KIT Mutation | Metastatic Gastrointestinal Stromal Tumor (GIST) | Advanced Gastrointestinal Stromal Tumor (GIST)

France
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Decitabine Alone or in Combination With Venetoclax, Gilteritinib, Enasidenib, or Ivosidenib as Maintenance Therapy for the Treatment of Acute Myeloid Leukemia in Remission

Acute Myeloid Leukemia

United States
M.D. Anderson Cancer Center

Recruiting

ASTX727, Venetoclax, and Gilteritinib for the Treatment of Newly Diagnosed, Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Acute Myeloid Leukemia | Myelodysplastic Syndrome | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI); Astex Pharmaceuticals, Inc.

Recruiting

ASTX727 and Dasatinib for the Treatment of Newly Diagnosed Philadelphia Chromosome or BCR-ABL Positive Chronic Myeloid Leukemia in Chronic Phase

Chronic Phase Chronic Myelogenous Leukemia | Philadelphia Chromosome Positive | BCR-ABL1 Positive Chronic Myelogenous Leukemia | BCR-ABL1 Positive

United States
Cancer Institute and Hospital, Chinese Academy...

Recruiting

Comparative Effectiveness of Palbociclib Plus AI Versus Fulvestrant for HR+/HER2- ABC (CAPACITY)

Hormone Receptor Positive Advanced Breast Cancer

China
Yonsei University

Not yet recruiting

24-month Ticagrelor-based Dual-antiplatelet Therapy Versus Clopidogrel-based Dual-antiplatelet theRapy aftEr 12 Months of DrUg-eluting Stent Implantation in High isChEmic Risk Patients: P-REDUCE Trial

High Ischemic Risk

Korea, Republic of
Royal Marsden NHS Foundation Trust
Pfizer; AstraZeneca; Institute of Cancer Research, United Kingdom; UNICANCER; Gustave... and other collaborators

Recruiting

A Trial of Early Detection of Molecular Relapse With Circulating Tumour DNA Tracking and Treatment With Palbociclib Plus Fulvestrant Versus Standard Endocrine Therapy in Patients With ER Positive HER2 Negative Breast Cancer (TRAK-ER)

HER2-negative Breast Cancer | ER+ Breast Cancer

United Kingdom, France
M.D. Anderson Cancer Center

Recruiting

Rituximab, Lenalidomide, Acalabrutinib, Tafasitamab Alone and With Combination Chemotherapy for the Treatment of Newly Diagnosed Non-germinal Center Diffuse Large B-Cell Lymphoma, Smart Stop Study

Diffuse Large B-Cell Lymphoma

United States
Qingdao Central Hospital

Recruiting

Osimertinib Combined With Bevacizumab in the Treatment Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions Metastatic Non-Small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung

China
Qingdao Central Hospital

Recruiting

Tyrosine Kinase Inhibitors in Metastastic Adenoid Cystic Carcinoma

Carcinoma, Adenoid Cystic

China
Washington University School of Medicine
Biovica

Recruiting

Treatment Monitoring of Patients Receiving CDK 4/6 Inhibitors for Hormone Receptor (HR) Positive, HER2 Negative Metastatic Breast Cancer (MBC) With or Without the Addition of DiviTum® Serum Thymidine Kinase 1 (TK1) Activity Testing

Breast Cancer | Cancer of the Breast

United States
Second Affiliated Hospital of Guangzhou Medical...

Recruiting

TACE Plus Multikinase Inhibitor and I-125 Seeds Brachytherapy for HCC With Branch PVTT

Hepatocellular Carcinoma Non-resectable

China
Centre Hospitalier Universitaire de Nīmes

Recruiting

Is There an Association Between Innate CD8+ T Cells and the Evolution of Tyrosine Kinase Inhibitor Resistance Mutations in Phi+ Hematological Malignancies. (TIPHI)

Leukemia | Chronic Leukemia | Myelogenous Leukemia | BCR-ABL Positive Acute Myeloid Leukemia

France
AstraZeneca

Recruiting

Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6) (SERENA-6)

ER-Positive HER2-Negative Breast Cancer

United States, Israel, Spain, Korea, Republic of, Italy, Poland, Belgium, Norway, Bulgaria, France, Germany, United Kingdom, Japan, Taiwan, Canada, Hungary, Australia, Austria, Portugal, Turkey, Russian Federation, Slovakia, Switzer...
Loxo Oncology, Inc.
Eli Lilly and Company

Recruiting

A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (BRUIN CLL-322)

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

Canada, United States, Korea, Republic of, Australia, China, Taiwan, Spain, Italy, United Kingdom, Japan, Ireland, Denmark, Hungary, Poland, Czechia, France, Israel, Singapore, Belgium, Sweden, Germany, Switzerland
Ono Pharmaceutical Co. Ltd

Recruiting

Study of Tirabrutinib (ONO-4059) in Patients With Primary Central Nervous System Lymphoma (PROSPECT Study)

Primary CNS Lymphoma | Refractory Primary Central Nervous System Lymphoma

United States
Fred Hutchinson Cancer Center
AstraZeneca

Recruiting

Acalabrutinib in Combination With Venetoclax for the Treatment of Refractory or Recurrent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Recurrent Small Lymphocytic Lymphoma | Refractory Chronic Lymphocytic Leukemia | Recurrent Chronic Lymphocytic Leukemia | Refractory Small Lymphocytic Lymphoma

United States
Novartis Pharmaceuticals

Recruiting

Study to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid Leukemia

Myeloid Leukemia, Philadelphia Positive

Korea, Republic of, Germany, France, Greece, Hungary, Italy, Japan, Russian Federation, Thailand, Turkey, China, United States, Netherlands, Poland
Royal Marsden NHS Foundation Trust
Pfizer; Hoffmann-La Roche

Recruiting

Fulvestrant, Ipatasertib and CDK4/6 Inhibition in Metastatic ER+/HER2- Breast Cancer Patients Without ctDNA Suppression (FAIM)

Advanced Breast Cancer | Metastatic Breast Cancer | ER+ Breast Cancer

United Kingdom
ITM Solucin GmbH

Recruiting

Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE (COMPOSE)

Neuroendocrine Tumors

United States, United Kingdom, Australia, Netherlands, France, Italy, Spain, Germany, Sweden, India
Ruth O'Regan
University of Rochester; Puma Biotechnology, Inc.

Recruiting

Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers

Breast Cancer | HER2-positive Breast Cancer | ER Positive Breast Cancer | PR-Positive Breast Cancer

United States
Fondazione Italiana Linfomi - ETS

Recruiting

Biological Insights of First Relapsed-refractory Patients With Mantle Cell Lymphoma: the MANTLE-FIRST BIO Study.

Mantle Cell Lymphoma

Italy
Emory University
National Cancer Institute (NCI); AstraZeneca

Recruiting

Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas

Mantle Cell Lymphoma | Marginal Zone Lymphoma | Lymphoplasmacytic Lymphoma | Lymphoproliferative Disorder | Indolent Non-Hodgkin Lymphoma | Grade 1 Follicular Lymphoma | Grade 2 Follicular Lymphoma | Grade 3a Follicular Lymphoma

United States
Novartis Pharmaceuticals

Recruiting

Asciminib Roll-over Study

Leukemia, Myelogenous, Chronic, BCR-ABL Positive | Chronic Myelogenous Leukemia

Denmark, Spain, France, Germany, Lebanon, Italy, Argentina, Czechia, Portugal, United Kingdom, Brazil, Mexico, Russian Federation, Taiwan, Austria, Canada, Korea, Republic of, Turkey, United States, Singapore, Japan, Bulgaria, Poland, Romani... and more
NKMAX Co., Ltd.

Recruiting

A Study to Evaluate the Safety and Anti-tumor Activity of SNK01 (NK Cells) Administered in Combination With Chemotherapy or Chemotherapy / Cetuximab in Local Advanced or Metastatic Non-small Cell Lung Cancer Patients Who Failed Tyrosine Kinase Inhibitor Treatment (SNK_ASTER)

Non-small Cell Lung Cancer

Korea, Republic of
Lady Davis Institute

Recruiting

Doxycycline vs Isotretinoin for Acneiform Eruptions of TKI

Acneiform Eruptions | Cancer, Treatment-Related

Canada
AstraZeneca

Recruiting

Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292) (CAPItello-292)

Locally Advanced (Inoperable) or Metastatic Breast Cancer

Spain, Denmark, United States, Korea, Republic of, Germany, Belgium, Vietnam, United Kingdom, France, Japan, Canada, China, India, Malaysia, Taiwan, Thailand, Australia, Turkey, Argentina, Brazil, Poland, Sweden, Italy
Guangdong Provincial People's Hospital

Not yet recruiting

Neoadjuvant Treatment With Palbociclib and Exemestane Plus Trastuzumab and Pyrotinib in Estrogen Receptor (ER)-Positive, HER2-positive Breast Cancer

Neoadjuvant Treatment for HER2-positive, ER-positive Breast Cancer
Haihe Biopharma Co., Ltd.

Not yet recruiting

Study of CYH33 in Combination With Endocrine Therapy With or Without Palbociclib in Patients With HR+, HER2- Advanced Breast Cancer

Advanced Breast Cancer
Blokhin's Russian Cancer Research Center

Recruiting

Analysis of Therapy Sequence in Women With HR+, HER2 - mBC in Moscow: A Multicenter Retrospective Observational Study.

Breast Cancer Stage IV

Russian Federation
Yazeed Sawalha

Recruiting

Zanubrutinib in Combination With R-CHOP (ZaR-CHOP) for Newly Diagnosed Diffuse Large B-Cell Lymphoma

Diffuse Large B-Cell Lymphoma | Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma | Transformed Marginal Zone Lymphoma to Diffuse Large B-Cell Lymphoma

United States
National Cancer Institute (NCI)

Recruiting

Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib and Rituximab) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma

Waldenstrom Macroglobulinemia | Lymphoplasmacytic Lymphoma

United States
Medical College of Wisconsin
H. Jean Khoury Cure CML Consortium

Recruiting

Protocol Number: HJKC3-0003. Treatment Free Remission After Combination Therapy With Asciminib (ABL001) Plus Tyrosine Kinase Inhibitors (TKI) in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed After a Prior Attempt at TKI Discontinuation

Chronic Phase Chronic Myelogenous Leukemia

United States
Chang Gung Memorial Hospital

Recruiting

Statin and Dual Antiplatelet Therapy to Prevent Early Neurological Deterioration in Branch Atheromatous Disease (SATBRAD)

Dual Antiplatelet Therapy | Acute Stroke | Statin

Taiwan
Wenjun Cheng

Not yet recruiting

Anlotinib Combined With Carboplatin/Paclitaxel as First-line Treatment in Patients With Advanced Ovarian Cancer

Neoplasms by Histologic Type | Neoplasms by Site | Carcinoma | Neoplasms, Glandular and Epithelial | Genital Neoplasms, Female | Endocrine System Diseases | Ovarian Diseases | Ovarian Neoplasms | Fallopian Tube Neoplasms | Carcinoma, Ovarian Epithelial | Angiogenesis | Genital Diseases, Female | Antineoplastic... and other conditions
Hoffmann-La Roche

Recruiting

A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Alectinib in Pediatric Participants With ALK Fusion-Positive Solid or CNS Tumors

ALK Fusion-positive Solid or CNS Tumors

United States, Korea, Republic of, China, Spain, Canada, Australia, United Kingdom, Denmark, France, Italy, Germany, Brazil
Instituto Oncológico Dr Rosell
Turning Point Therapeutics, Inc.

Recruiting

Phase I Study of Repotrectinib and Osimertinib in NSCLC Patients (TOTEM)

Nsclc

Spain
Emory University
National Cancer Institute (NCI)

Recruiting

MRX-2843 and Osimertinib for the Treatment of Advanced EGFR Mutant Non-small Cell Lung Cancer

Metastatic Lung Non-Small Cell Carcinoma | Stage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Advanced Lung Non-Small Cell Carcinoma

United States
Second Affiliated Hospital, School of Medicine,...
Sun Yat-sen University; Peking University International Hospital; Zhejiang University

Not yet recruiting

TKIs vs. Pertuzumab in HER2+ Breast Cancer Patients With Active Brain Metastases (HER2BRAIN)

HER2-positive Breast Cancer | Brain Metastases

China
Washington University School of Medicine
Apollomics Inc.

Recruiting

Safety and Efficacy of Combining APL-101 With Frontline Osimertinib in Patients With EGFR-mutated Metastatic Non-small Cell Lung Cancer (NSCLC)

Metastatic Non Small Cell Lung Cancer

United States
National Cancer Institute (NCI)

Recruiting

Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma

Lymphoma | Diffuse Large B-Cell Lymphoma | Burkitt Lymphoma | Non-Hodgkin Lymphoma

United States
Centre Leon Berard

Recruiting

Efficacy of Regorafenib Combined With Best Supportive Care as Maintenance Treatment in High Grade Bone Sarcomas Patients (REGOMAIN)

Osteosarcoma | Bone Sarcoma

France

Search clinical trials for: Dual receptor Tyrosine Kinase Inhibitor

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Bahrain

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations